Fentanyl transdermal patch - Lavipharm

Drug Profile

Fentanyl transdermal patch - Lavipharm

Alternative Names: Durfenta; Fentadur; Fentanilo Parke Davis; Fentanyl Pfizer; Lafene; Opiodur; Recorfen

Latest Information Update: 13 Mar 2015

Price : $50

At a glance

  • Originator Lavipharm S.A.
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Mar 2007 Preregistration for Pain in United Kingdom (Transdermal)
  • 28 Mar 2006 Phase-III clinical trials in Cancer pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top